STERIS plc (Ireland)

Valuation Analysis

About the Company

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope

STERIS plc (Ireland) Stock at a Glance

STERIS plc (Ireland) (STE) is currently trading at $207.56 with a market capitalization of $20.2B. The trailing P/E ratio stands at 26.17x, with a forward P/E of 17.14x. The 52-week range spans from $195.14 to $269.44; the current price is 23% below the yearly high. Year-over-year revenue growth stands at +7.3%. The net profit margin stands at 13.18%.

💰 Dividend

STERIS plc (Ireland) pays an annual dividend of $2.52 per share, representing a yield of 1.21%. The payout ratio stands at 31.02%.

📊 Analyst Rating

7 analysts rate STERIS plc (Ireland) (STE) on consensus: Buy. The average price target is $256.86, implying +23.75% from the current price. Analyst price targets range from $225.00 to $280.00.

STERIS plc (Ireland): The Investment Case in Detail

STERIS plc (Ireland) (STE) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 52.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 44.24% gross margin and 20.04% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 23.75% upside from current levels — analyst sentiment is firmly constructive.

Valuation in Context

The PEG ratio at 1.41 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 17.14x is meaningfully below the trailing 26.17x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 23.75% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy STERIS plc (Ireland)?

Compare top-rated brokers — low fees, trusted providers, fully regulated.